Sepsis leadership T2 Biosystems has two FDA-cleared products for rapid sepsis detection and exclusive US distribution partnerships, presenting a clear cross-sell opportunity to hospitals and health systems seeking to strengthen rapid sepsis diagnostics across emergency, ICU, and core lab settings.

Lyme expansion The recent launch of the T2Lyme Panel and planned early 2025 LDT introduction create a pathway to expand oncology and infectious disease portfolios within existing accounts, especially in institutions prioritizing rapid tick-borne pathogen detection.

Strategic partnerships News of Cardinal Health exclusivity in the US and extended Vizient supplier agreement indicate distributors and GPOs are critical channels; leverage these relationships to target mid-to-large hospital networks and integrated delivery organizations seeking rapid adoption of FDA-cleared platforms.

Financial stability With a multi-year funding footprint and a run-rate revenue in the mid-range of the diagnostic market, there is runway for channel-focused campaigns, pilot programs, and reimbursement-focused value storytelling aimed at ID, pathology, and laboratory leadership.

Tech-enabled outreach The use of a modern tech stack (CRM, ERP, analytics, and collaboration tools) supports targeted account-based marketing and procurement alignment; propose integrated demonstrations, ROI analyses, and clinical impact data to accelerate procurement conversations with prospective hospital clients.